Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is set to announce third quarter earning results on Monday 9th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, INFI to report 3Q20 loss of $ 0.16 per share from revenue of $ 0.16 million.
For the full year, analysts anticipate top line of $ 2.19 million, while looking forward to loss of $ 0.64 per share bottom line.
Previous Quarter Performance
Infinity Pharmaceuticals, Inc. posted loss for the second quarter of $ 0.16 per share, from the revenue of $ 0.36 million. The quarterly revenues swell 38.46 percent compared with the same quarter last year. According to street consensus, INFI was expected to report 2Q20 loss of $ 0.19 per share from revenue of $ 0.16 million. The bottom line results beat street analysts by $ 0.03 or 15.79 percent, at the same time, top line results outshined analysts by $ 0.20 million or 125.00 percent.
Stock Performance
On Friday, shares of Infinity Pharmaceuticals, Inc. has traded high as $ 1.18 and has cracked $ 1.09 on the downward trend, reaching $ 1.13 with volume of 303.00 thousand shares.
According to the previous trading day, closing price of $ 1.13, representing a 83.33 % increase from the 52 week low of $ 0.60 and a 34.52 % decrease over the 52 week high of $ 1.68.
The company has a market capital of $ 66.52 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Infinity Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.infi.com
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc.
